Clinical Trial Update: A Study of Emicizumab Administered Subcutaneously (SC) in Pediatric Participants With Hemophilia A and Factor VIII (FVIII) Inhibitors [Phase 3]

View source ↗

Summary

Phase 3 study update on subcutaneous emicizumab in pediatric Hemophilia A patients with FVIII inhibitors; trial completed with posted results.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hemophilia

Drugs mentioned

• Emicizumab (emicizumab)

Snippet

Sponsor: Hoffmann-La Roche | Conditions: Hemophilia A | Phase 3 | Status: COMPLETED | Results posted: 2019-04-10